2021-01-04,b'$SNDX price drop of -2.67 % with an ok PE -15.37 and beta 1.04 https://t.co/dmXhzDF1Jl'
2021-01-03,b'$SNDX $22.24 -0.61  -2.67%SNDX-5613 (AUGMENT-101) Relapsed/refractory (R/R) acute leukemias Early 2021 Phase 1 full data to be presented due early 2021. Phase 2 trial to commence also in early-2021.\n$TRVNN/ATRV027 COVID-19Phase 1b 1Q 2021\ntop-line data due 1Q 2021.'
2021-01-03,b'$SNDX Turn Green.. NOT Red... -2.67 %  https://t.co/dmXhzDF1Jl'
2021-01-02,b'$SNDX this is the time you buy equities thank you fed  -2.67 % change recently https://t.co/TVk8JtQe7k'
2021-01-02,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-02,b'$SNDX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators: https://t.co/1XrOJOTRbB #SyndaxPharmaceuticals #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/Uil85Gi5zp'
2021-01-02,"b'$SNDX Syndax Pharmaceuticals, I #LeaderPullBack Close: 22.24 Liq: $19M https://t.co/fhnFbaAfrK'"
2021-01-02,b'$SNDX price drop of -2.67 % with an ok PE -15.37 and beta 1.04 https://t.co/dmXhzDF1Jl'
2021-01-02,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-02,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Melanoma ph3\n$NVS Iptacopan(Factor B) IgAN ph2\n$SRPT SRP-9001 DMD ph2\n$SNDX-5613 MLL-r/NPM1 AML ph1\n\nCovid-19 Vaccine:\n$AZN US ph3\n$JNJ US ph3\n$NVAX UK ph3 https://t.co/GvakdEQgNI'
2021-01-01,b'$SNDX what a Company  -2.82 % change recently https://t.co/FIsUNOAQyx'
2021-01-01,b'$SNDX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators: https://t.co/osxjfjg5k8 #SyndaxPharmaceuticals #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/VX17zShcrF'
2021-01-01,"b'$SNDX Syndax Pharmaceuticals, I #LeaderPullBack Close: 22.24 Liq: $19M https://t.co/fhnFbaAfrK'"
2021-01-01,b'$SNDX was analyzed by 6 analysts. The buy consensus is at 93%. So analysts seem to be very confident about $SNDX. https://t.co/hdcCW0nkr8 https://t.co/RghEavDq8i'
2020-12-31,"b'Large Print $SNDX Size: 297896 Price: 22.24 Time: 1600 Amount: $6,625,207.04'"
2020-12-31,b'$SNDX Always buy on Fear ..\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd\xef\xbf\xbd -3.40 % change recently https://t.co/FIsUNOAQyx'
2020-12-30,b'$SNDX what a Company  -3.34 % change recently https://t.co/dmXhzDF1Jl'
2020-12-30,"b'Large Print $SNDX Size: 249300 Price: 23 Time: 1457 Amount: $5,733,900.00'"
2020-12-30,"b'Large Print $SNDX Size: 125000 Price: 23.195 Time: 1456 Amount: $2,899,375.00'"
2020-12-30,b'Quick Trade Idea: $SNDX  Syndax Pharmaceuticals  Inc.\nOn 12/30/2020 an alert was issued to buy SNDX at 23.3 with a profit target of 24.58 and a stop loss of 21.44 based on a RSI alert. \n[Stock Details]  https://t.co/LTBIzXxoUI'
2020-12-28,"b'RT @TomSilver39: Barclays:"" SCENARIO ANALYSIS OF M&amp;A VALUATIONS FOR Barclays COVERAGE: $KPTI, $EPZM, $EXEL, $AGIO, $RCUS, $DCPH, $CTMX, $NK\xe2\x80\xa6'"
2021-01-08,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-08,b'$SNDX auction is now open. 3.82 % change recently https://t.co/FIsUNOAQyx'
2021-01-08,b'$SNDX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators: https://t.co/aQVjCZ1TSk #SyndaxPharmaceuticals #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/gXriUxzJdr'
2021-01-08,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-08,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-07,b'$SNDX Major changes in stock price 3.12 % change recently https://t.co/TVk8JtQe7k'
2021-01-07,b'https://t.co/j6Wk71MhJM Syndax Pharmaceuticals Inc The network concludes the value of this company should remain flat in the coming days and has no clear long term directional perspective $SNDX #stocks #bitcoin #trader'
2021-01-07,b'RT @buysidebio: Keep an eye on Biomea IPO for 21. Competitor to $KURA &amp; $SNDX https://t.co/sfin2MgsbB'
2021-01-07,b'RT @buysidebio: Keep an eye on Biomea IPO for 21. Competitor to $KURA &amp; $SNDX https://t.co/sfin2MgsbB'
2021-01-07,b'RT @buysidebio: Keep an eye on Biomea IPO for 21. Competitor to $KURA &amp; $SNDX'
2021-01-07,b'Keep an eye on Biomea IPO for 21. Competitor to $KURA &amp; $SNDX https://t.co/sfin2MgsbB'
